CD274 and gastric cancer: Results from CheckMate 649 showed that nivolumab with chemotherapy improved OS [hazard ratio (HR) 0.71 (98.4% CI 0.59–0.86); p < 0.0001] and PFS [HR 0.68 (98% CI 0.56–0.81); p < 0.0001] in GC patients with a PD-L1 CPS (combined positive score) of five or more when compared with chemotherapy alone (Janjigian et al., 2021).